ArticleIJID regions2025
HIV-1 genetic diversity and pretreatment drug resistance survey prior to dolutegravir introduction in Senegal.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to document the prevalence of pretreatment drug resistance in antiretroviral therapy-naïve patients in Senegal, describe mutation profiles, and evaluate their potential impact on future therapy. Methods: A pretreatment drug resistance survey was carried out in 35 sites throughout the country between 2017 and 2018 using dried blood spots and whole blood samples. Amplification and sequencing were performed on the partial reverse transcriptase (RT) gene using the Agence Nationale de Recherches sur le Sida et les hépatitis virales (ANRS: French National Agency for Research on acquired immunodeficiency syndrome [AIDS] and Viral Hepatitis)/AC11 method at the HIV National Reference Laboratory. Surveillance drug resistance mutations (SDRM) were analyzed using the Calibrated Population Resistance v8.1, and the proportion of SDRM was evaluated after grouping sites by geographical areas. Results: A total of 237 samples from different patients were analyzed, and 131 (55.3%) were successfully amplified and sequenced. Among these, 14 (10.7%) harbored SDRM with significant variability across regions. For nucleoside reverse transcriptase inhibitors (NRTI), the SDRM rate was highest in Dakar (9.1%), followed by the Southwest (5.3%) and the Southeast (4.2%). For non-NRTIs (NNRTIs), the highest rate was observed in the Southeast (20.8%), followed by Dakar (13.6%), the Midwest (8.3%), and the Southwest (3.6%). Among NRTIs, the most frequent mutation was M184V (3/6), conferring high-level resistance to lamivudine and emtricitabine, and K103N (11/12) among NNRTIs, conferring resistance to efavirenz and nevirapine. Notably, four sequences harbored SDRMs for both NRTI and NNRTI, reflecting overlapping resistance in some patients. The higher prevalence of NNRTI resistance is consistent with the lower genetic barrier of these drugs compared to NRTIs, which may facilitate the emergence of pretreatment drug resistance. Conclusion: Through a quasi-national survey, an intermediate level of NNRTI resistance was observed, with regional disparities in Senegal. These findings highlight the limitations of NNRTI-based first-line regimens in Senegal and support the transition to other antiretroviral therapy regimens, such as dolutegravir-based therapy in newly infected individuals as well as in treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.